Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
暂无分享,去创建一个
J. Maciejewski | H. Carraway | A. Advani | M. Sekeres | M. Kalaycio | A. Nazha | B. Przychodzen | C. Hirsch | S. Mukherjee | A. Gerds | R. Sobecks | C. Saygin | B. Hamilton | D. Abounader | Christopher Goebel